MET and hepatocellular carcinoma: Overall, our findings provide an insight into (1) the inhibitory role of Gα12 in miR-122 targeting c-Met, and (2) the crosstalk between GPCR and c-Met in HCC, implying that intervention of the Gα12 pathway may be of help to improve c-Met-targeted therapy.